Other (Income)/Deductions - Net (Detail) (USD $) In Millions	3 Months Ended				9 Months Ended
	Oct. 02, 2011		Oct. 03, 2010		Oct. 02, 2011		Oct. 03, 2010
Other (Income) Deductions - Net [Line Items]
Interest income	$ (110)	[1]	$ (100)	[1]	$ (332)	[1]	$ (297)	[1]
Interest expense	423	[1]	427	[1]	1,285	[1]	1,338	[1]
Net interest expense	313		327		953		1,041
Royalty-related income	(135)		(158)		(447)		(395)
Net losses/(gains) on asset disposals	18		(13)		(8)		(243)
Certain legal matters, net	132	[2]	712	[2]	619	[2]	886	[2]
Certain asset impairment charges	105	[3]	1,478	[3]	585	[3]	1,710	[3]
Other, net	105		3		76		37
Other deductions-net	538		2,349		1,778		3,036
Certain asset impairment charges					773		2,956
Wyeth [Member]
Other (Income) Deductions - Net [Line Items]
Certain asset impairment charges					585		1,700
Wyeth [Member] | In Process Research And Development [Member]
Other (Income) Deductions - Net [Line Items]
Certain asset impairment charges					440		900
Wyeth [Member] | Indefinite Lived Brands [Member]
Other (Income) Deductions - Net [Line Items]
Certain asset impairment charges							600
Wyeth [Member] | Developed Technology Rights [Member]
Other (Income) Deductions - Net [Line Items]
Certain asset impairment charges					$ 145		$ 200

[1] Interest income increased in both periods of 2011 primarily due to higher cash balances. Interest expense decreased in both periods of 2011 due to lower long- and short-term debt balances and the conversion of some fixed-rate liabilities to floating-rate liabilities.

[2] In the first nine months of 2011, primarily relates to charges for hormone-replacement therapy litigation (see Note 14. Legal Proceedings and Contingencies). In both periods of 2010, primarily includes a charge for asbestos litigation related to our wholly owned subsidiary, Quigley Company, Inc. (see Note 14. Legal Proceedings and Contingencies).

[3] Substantially all of these asset impairment charges are related to intangible assets, including in-process research and development (IPR&D) assets, that were acquired as part of our acquisition of Wyeth. The impairment charges are determined by comparing the estimated fair value of the assets as of the date of the impairment to their carrying values as of the same date. In the first nine months of 2011, we recorded impairment charges of $585 million, which included approximately $440 million of IPR&D assets, primarily related to two compounds for the treatment of certain autoimmune and inflammatory diseases, and approximately $145 million of Developed Technology Rights. These impairment charges reflect, among other things, the impact of new scientific findings and updated commercial forecasts. In the first nine months of 2010, we recorded impairment charges of $1.7 billion, which include (i) approximately $900 million of IPR&D assets, primarily Prevnar/Prevenar 13 Adult, a compound for the prevention of pneumococcal disease in adults age 50 and older, and Neratinib, a compound for the treatment of breast cancer; (ii) approximately $600 million of indefinite-lived Brands, related to Third Age, infant formulas for the first 12-36 months of age, and Robitussin, a cough suppressant; and (iii) approximately $200 million of Developed Technology Rights, primarily Protonix, a product that treats erosive gastroesophageal reflux disease. These impairment charges, most of which occurred in the third quarter of 2010, reflect, among other things, the following: for IPR&D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risk associated with these assets; for Brand assets, the current competitive environment and planned investment support; and, for Developed Technology Rights, an increased competitive environment.